

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001773588
Filer CCC XXXXXXXXX
Is this a LIVE or TEST Filing? LIVE TEST

Submission Contact Information

Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer Apellis Pharmaceuticals, Inc.
SEC File Number 001-38276
Address of Issuer 100 FIFTH AVENUE
WALTHAM
MASSACHUSETTS
02451
Phone 617-977-5700
Name of Person for Whose Account the Securities are To Be Sold Townsend Adam J.

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Former Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	220961	3924267.36	125682260	05/12/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from	Is this	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
--------------------	-------------------	-----------------------------------	---------------------	---------	---------------------	-------------------------------	-----------------	---------------------

			Whom Acquired	a Gift?		
Common	05/12/2025	Option Granted - 02/08/2019	Issuer	<input type="checkbox"/>	5000	05/12/2025 Cash
Common	05/12/2025	Option Granted - 11/16/2018	Issuer	<input type="checkbox"/>	172500	05/12/2025 Cash
Common	01/28/2025	Restricted Stock Vesting	Issuer	<input type="checkbox"/>	1180	01/28/2025 Compensation
Common	01/21/2025	Restricted Stock Vesting	Issuer	<input type="checkbox"/>	5661	01/21/2025 Compensation
Common	01/16/2025	Restricted Stock Vesting	Issuer	<input type="checkbox"/>	3736	01/16/2025 Compensation
Common	01/12/2025	Restricted Stock Vesting	Issuer	<input type="checkbox"/>	4138	01/12/2025 Compensation
Common	04/30/2024	ESPP Purchase	Issuer	<input type="checkbox"/>	501	04/30/2024 Cash
Common	02/10/2024	Restricted Stock Vesting	Issuer	<input type="checkbox"/>	1196	02/10/2024 Compensation
Common	01/28/2024	Restricted Stock Vesting	Issuer	<input type="checkbox"/>	969	01/28/2024 Compensation
Common	01/21/2024	Restricted Stock Vesting	Issuer	<input type="checkbox"/>	5572	01/21/2024 Compensation
Common	01/12/2024	Restricted Stock Vesting	Issuer	<input type="checkbox"/>	4637	01/12/2024 Compensation
Common	04/28/2023	ESPP Purchase	Issuer	<input type="checkbox"/>	412	04/28/2023 Cash
Common	02/21/2023	Restricted Stock Vesting	Issuer	<input type="checkbox"/>	1430	02/21/2023 Compensation
Common	02/10/2023	Restricted Stock Vesting	Issuer	<input type="checkbox"/>	1562	02/10/2023 Compensation
Common	01/28/2023	Restricted Stock Vesting	Issuer	<input type="checkbox"/>	1324	01/28/2023 Compensation
Common	01/21/2023	Restricted Stock Vesting	Issuer	<input type="checkbox"/>	4600	01/21/2023 Compensation
Common	04/29/2022	ESPP Purchase	Issuer	<input type="checkbox"/>	769	04/29/2022 Cash
Common	02/10/2022	Restricted Stock Vesting	Issuer	<input type="checkbox"/>	1449	02/10/2022 Compensation
Common	01/28/2022	Restricted Stock Vesting	Issuer	<input type="checkbox"/>	1075	01/28/2022 Compensation
Common	04/30/2021	ESPP Purchase	Issuer	<input type="checkbox"/>	792	04/30/2021 Cash
Common	02/10/2021	Restricted Stock Vesting	Issuer	<input type="checkbox"/>	1655	02/10/2021 Compensation
Common	10/30/2020	ESPP Purchase	Issuer	<input type="checkbox"/>	321	10/30/2020 Cash
Common	04/30/2020	ESPP Purchase	Issuer	<input type="checkbox"/>	482	04/30/2020 Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice 05/12/2025

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Adam J Townsend

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)